While the COVID-19 pandemic seems likely to remain the dominant headline in 2021, a host of other potential occurrences could have big impacts this year. Precision's Dan Danielson joins a variety of industry experts to discuss what's ahead in 2021 for healthcare and pharma beyond the pandemic.
Recent reforms on price transparency will substantially increase payers' workloads. The Trump administration and CMS recently released a final rule that will require payers to post documents that include in-network and out-of-network provider rates and in-network drug prices starting in 2022. And in 2023, private insurers will be required to provide negotiated provider cost-sharing estimates and up-front prices to members.
Leadership teams from the 2020 Manny Award winners and finalists participated in a comprehensive Q&A forum on a variety of healthcare industry themes and trends.
LEADING BIO-ENGINEERING AND MANUFACTURING SERVICES FIRM CATALYZES THE LAUNCH OF PRECISION’S CELL AND GENE THERAPY OFFERING—'PRECISION ADVANCE’—ADDRESSING THE UNIQUE CHALLENGES OF CELL & GENE THERAPY INNOVATORS, FROM DEVELOPMENT THROUGH COMMERCIALIZATION
The National Comprehensive Cancer Network (NCCN) recommended zanubrutinib, approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL), for treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The AJMC asked Precision's Erin Lopata to weigh in on how to respond when a drug is added to NCCN guidelines before the FDA approves the indication.
The Administration's recently released final rule on transparency in healthcare coverage is set to take effect January 1, 2023. The rule aims to provide increased visibility into the cost of care for treatments and procedures and to support cost-conscious decisions about healthcare services. Precision's Erin Lopata provides an overview of what you need to know now.
Update on HHS drug pricing rules: An HHS final rule targeting Medicare Part D rebates was issued on November 30, 2020. Unlike the interim rule, the final rule includes only rebates in Part D, not Medicaid managed care, and it pushes back implementation from Jan. 1, 2020, to Jan. 1, 2022. Comments on the interim final rule following the Most Favored Nation model are due by Jan. 26, 2021. Precision's Andrew Cournoyer and Ryan Cox weigh in on the problems and concerns with both rules.
The COVID-19 pandemic consumed most of 2020. While it was the big story last year, it wasn't the only story. Precision's Dan Danielson and other experts weigh in on the oversized impact of COVID-19 on the pharma industry, and other trends from 2020.
Value-based care has been replacing the traditional fee-for-service model in the United States. Value-based care models and population health are essential to improving health and reducing health care costs. Precision's Ryan Cox discusses how value-based payment models in chronic kidney disease can improve total cost and quality of care for patients.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
